Cipla gets US regulatory nod for new drug

Mumbai: Global drug major Cipla Ltd announced on Friday that it had received approval of the United States Food and Drug Administration (USFDA) for its new drug Darifenacin tablets for treating bladder symptoms.

“The generic tablet in 7.5mg and 15 mg (dose) are used for treating overactive bladder with symptoms of urge in urinary incontinence, urgency and frequency,” said the city-based company in a statement here.

The new drug is AB-rated generic equivalent of Allergan’s Enablex tablets.

The company will launch the product soon.

According to IMS Health, the American firm that provides information, services and technology for the healthcare industry, Enablex tablets and generic equivalents had US sales of $85 million for the 12-month period ending June.